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Abstract
Background: Early diagnosis and treatment of Mycobacterium tuberculosis infection can prevent most deaths
resulting from this pathogen; however, multidrug-resistant strains present serious threats to global tuberculosis
control and prevention efforts. In this study, we identified antigens that could be used for the serodiagnosis of
drug-resistant M. tuberculosis strains, using a proteomics-based analysis.
Results: Serum from patients infected with drug-resistant or drug-susceptible M. tuberculosis strains and healthy
controls was subjected to two-dimensional gel electrophoresis using a western blot approach. This procedure
identified nine immunoreactive proteins, which were subjected to MALDI-TOF-MS analysis. Six recombinant
proteins, namely rRv2031c, rRv0444c, rRv2145c, rRv3692, rRv0859c, and rRv3040, were expressed and used to
determine the immuno-reactivity of 100 serum samples. Antibody reactivity against rRv2031c, rRv3692, and
rRv0444c was consistently observed. Among them, the best sensitivity and specificity of rRv3692 were 37% and
95% respectively. Furthermore, when rRv2031c and rRv3692 or rRv2031c, rRv3692, and rRv0444c were combined in
2:1 or equal amounts, the assay sensitivity and specificity were improved to 56.7% and 100% respectively.
Conclusions: These results suggest that Rv2031c, Rv3692, and Rv0444c are possible candidate biomarkers for
effective use in the serodiagnosis of drug-resistant tuberculosis infections, and a combined formula of these
antigens should be considered when designing a subunit assay kit.
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Background
More than one-third of the world’sp o p u l a t i o ni s
infected with tubercle bacilli. Poor adherence to tuber-
culosis (TB) control programs, the subsequent emer-
gence of drug-resistant strains and the widespread
prevalence of HIV have contributed to the resurgence of
this disease [1]. Multidrug-resistant tuberculosis (MDR-
TB) and extensively drug-resistant tuberculosis present
serious threats to global TB control efforts. The World
Health Organization estimated that the number of new
MDR-TB cases in 2004 was 425, 000, and 60% of these
cases were located in China, India, and the Russian Fed-
eration [2,3].
Most TB-associated deaths are preventable with early
diagnosis and treatment [4], and it has been suggested
that a quick and accurate tool for early TB diagnosis
could save up to 625, 000 lives each year [5]. Currently,
optimal diagnostics for TB are a demanding task and
new procedures are urgently needed. In endemic areas,
sputum-smear microscopy is often the only available
and affordable diagnostic test but is only 50-70% sensi-
tive. The diagnostic gold standard is considered to be
culturing Mycobacterium tuberculosis,a si ti ss e n s i t i v e
and specific in cases of smear-positive TB. However,
results usually take two to four weeks and this test is
not routinely used in countries with high prevalence of
TB. Recently developed PCR-based tests or interferon-
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® TB-Gold, are
expensive and require a certain level of expertise [4].
Antibody detection is one of the most common
approaches used in the diagnosis of infectious diseases.
Antibody production is typically the result of antigen
exposure from an infection, and dominant antigens are
the primary target for diagnostic and immunoprophylac-
tic therapies. Detection of M. tuberculosis antigens
released during the active disease stage has been consid-
ered a specific and ideal approach in the serodiagnosis
of TB because these antigens represent an early disease
state [6]. More specifically, antigens including antigen 5
(38 kDa antigen, Rv0934), 27 kDa antigen (MPT51,
Rv3803c), 30 kDa antigen (Ag85B, MPT59, Rv1886c),
P32 (Rv3804c), 88 kDa antigen (MTB81, Rv1837c), anti-
gen 60 (A60), cord factor, Kp90 and LAM could poten-
tially be used in the serodiagnosis of TB [7]. To date,
there are no commercially available serodiagnostic tests
for TB. In particular, there is no routine laboratory test
for drug-resistant TB with sufficient sensitivity and
specificity.
Proteomics is a powerful tool for studying the protein
composition of complex biological samples. Protein
expression profiles of M. tuberculosis under various
growth conditions, genetic backgrounds and geographic
distribution have been investigated [8-15]. The applica-
tion of immunoproteomics, combining 2-DE with
immunoblotting to find protein candidates for serodiag-
nostics, is a powerful tool [16-18]. Using this approach,
Bassey et al. found some heterogeneity in the responses
to M. tuberculosis antigens with different patient sera
[19]. Karen et al. identified 12 immunogenic proteins
from actively replicating H37Rv culture filtrates [20].
However, until recently, there was little information
regarding the immunogenicity profiles associated with
drug-resistant M. tuberculosis strains.
Therefore, the main objective of this study was to
evaluate differences between antigen expression and the
respective immunoreactivity profiles of drug-susceptible
and drug-resistant M. tuberculosis strains using an
immunoproteomic approach. Identified proteins were
subsequently cloned, expressed and purified, and their
subcellular location was determined. Antibody reactivity
against these proteins was detected by ELISA to evaluate
the potential of these antigens to be used as biomarkers
for early identification of MDR-TB.
Results and discussion
M. tuberculosis 2-DE profile of whole cell proteins
Two-dimensional gel electrophoresis analysis was per-
formed on five MDR clinical isolates and H37Rv, which
is a strain that is sensitive to all four first-line TB anti-
biotics. Representative 2-DE gels of these strains are
presented in Figure 1. In the pH range of 4-7,
approximately 1000 silver-stained protein spots were
reproducibly detected in all strains using the PDQuest
version 6.0 software. Three or more gels for each strain
were analyzed and compared during the course of this
analysis. Only gels with similar normalized volumes for
each sample analyzed were selected for western blot
analysis.
Identification of immunoreactive proteins
Proteins from MDR and antibiotic-susceptible strains
were examined by western blot for immunoreactivity to
serum from patients infected with drug-resistant M.
tuberculosis. Pooled serums from patients infected with
antibiotic-susceptible M. tuberculosis were used as nega-
tive controls. Figure 1B, C reflect representative anti-
genic profiles using serum collected from individuals
infected with drug-resistant M. tuberculosis and drug-
susceptible M. tuberculosis, respectively. Immunoreactive
protein spots selected for further analysis were present
on blots probed with patient serum but not visible on
blots probed with negative controls. Protein mass finger-
printing of trypsin digest fragments was performed on
these proteins, and the results are summarized in Table
1 (including data sourced from Additional files 1, 2, 3,
4, 5, 6, 7 &8). Protein characterization was conducted
using MALDI-TOF-MS and MALDI-TOF-MS/MS ana-
lysis, and the data were compared with the MASCOT
database for sequence matches. Identification of proteins
was based on the probability scores for the matches,
molecular mass, pI, number of peptide matches and the
percentage of the total translated ORF sequence covered
by the peptides.
Pooled sera from patients diagnosed with drug-resis-
tant M. tuberculosis infection were used to identify
immunodominant antigens. The identification of M.
tuberculosis proteins by human sera suggested that these
antigens were expressed in vivo and were capable of eli-
citing humoral responses. These antigens could there-
fore be considered attractive immunodiagnostic
candidates. A total of nine immunoreactive protein
s p o t s( F i g u r e s1 ,2 )w e r ei d e n t i f i e da n da r er e p o r t e di n
Table 1. Among them, the M. tuberculosis proteins
Rv0639, Rv3028c, Rv3040, Rv2145c, Rv0859c, Rv3692
and Rv0444c were only present when MDR strains were
probed with serum from patients infected with MDR M.
tuberculosis. These proteins were not observed on mem-
branes probed with negative control serum. Rv1310 was
identified on all membranes examined. Rv2031c was
only present on membranes blotted with drug-suscepti-
ble strains and serum from patients infected by antibio-
tic-sensitive clinical strains (Figure 3).
The nine unique MDR proteins were divided into four
functional groups. The first group encompassed metabolic
pathway-associated proteins, including carbohydrate
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Page 2 of 10Figure 1 Comparison of 2-DE analysis and western blot analysis of different M. tuberculosis bacterial proteins at pH 4-7.8 0μg of total
protein lysates from M. tuberculosis were loaded in the first dimension and approximately 1000 spots were detected after silver staining. Proteins
identified were indicated by spot number and in Table 1. (A) 2-DE analysis of cell lysates from antibiotic-susceptible strains (a1), multi-drug
resistant strains (a2). (B) Western blot analysis of 2-DE maps of M. tuberculosis using pooled serum from patients infected with MDR clinical
strains. Protein lysates examined were from sensitive (b1), multi-drug resistant strains (b2). (C) Western blot analysis of 2-DE maps of M.
tuberculosis using pooled serum from patients infected with antibiotic-sensitive clinical strains. Protein lysates were from sensitive (c1), multi-drug
resistant strains (c2). Gels were electroblotted onto PVDF membranes using a semidry transfer unit. All seras were used at the same dilution to
1:400. Labeled protein spots were excised from corresponding 2DE reference gels run in parallel and subsequently identified using MALDI-TOF-
MS and MALDI-TOF-MS/MS analysis.
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Page 3 of 10Table 1 Immunoreactive protein spots identified by MALDI-TOF-MS
Spot
No
a.
NCBI
accession
no.
b
Sanger
I.D.
Protein identification MW/PI Mascot
score
c
GRAVY
score
d
2D immunoreactivity
Theoretical Experimental Sensitive
M.
tuberculosis
RIF
r M.
tuberculosis
MDR M.
tuberculosis
M1 gi|1322434 Rv1310 ATP synthase beta chain
(atpD)
53093.32/
4.76
53061.2/4.86 433, 57 -0.168 S-sera
e All sera All sera
M2 gi|2916918 Rv0859c Acyl-CoA thiolase (fadA) 42413.60/
5.14
42387.8/5.2 181, 32 0.035 R-sera ––
M3 gi|
15610828
Rv3692 Methanol dehydrogenase
regulatory protein(moxR2)
37903.47/
5.51
37904.3/5.43 192, 20 -0.002 – R-sera –
M4 gi|
15610165
Rv3028c electron transfer
flavoprotein (alpha
subunit) (fixB, etfA)
31690.02/
4.61
31699.8/4.47 746, 68 0.358 –– R-sera
M5 gi|2791638 Rv3040 Conserved hypothetical
protein
31484.26/
4.50
31465.7/4.65 98, 6 -0.297 –– R-sera
M6 gi|2104333 Rv2145c antigen 84(wag31) 28276.23/
4.75
28260.1/4.80 133, 49 -0.726 –– R-sera
M7 gi|
15607779
Rv0639 Transcription
antitermination protein
(nusG)
25413.54/
4.59
25431.0/4.70 175, 23 -0.180 –– R-sera
M8 gi|
15607585
Rv0444c Conserved hypothetical
protein
23882.15/
5.82
23883.0/5.81 75, 13 0.062 – R-sera –
S1 gi|2896768 Rv2031c Heat Shock Protein hspX
(14-kDa antigen)
16226.30/
4.90
16217.2/5.0 209, 35 -0.52 – S-sera –
a) Spot numbers refer to the numbers on the 2-DE gels showed in Figure 1A-C.
b) Accession no. obtained from the MASCOT results of MALDI-TOF/TOF from the NCBInr database http://www.ncbi.nlm.nih.gov.
c) MASCOT score and percent sequence coverage of all tryptic peptides identified by MALDI-TOF-MS/MS. MASCOT protein scores (based on combined MS and
MS/MS spectra (Additional files 1, 2, 3, 4, 5, 6, 7 and 8) greater than 72 were considered statistically significant (p ≤ 0.05).
d) Grand average of hydropathy.
e) Anti-sera from TB patients infected with antibiotic-sensitive M. tuberculosis.
f) Anti-sera from TB patients infected with drug-resistant M. tuberculosis
Figure 2 SDS-PAGE analysis of recombinant proteins. Rv0859c,
Rv2031c, Rv2145c, Rv3692, Rv0444c and Rv3040 were subjected to
SDS-PAGE and stained with Coomassie blue. Molecular size markers
are indicated on the left in kDa.
Figure 3 Subcellular localization of M. tuberculosis H37Rv
proteins. Lysates from M. tuberculosis H37Rv were fractionated into
cytosol (CY), cell membrane (CM), cell wall (CW) and culture filtrate
(CF) fractions. These fractions were normalized for total protein
content (50 μg) before SDS-PAGE and then electroblotted onto a
PVDF membrane and probed with rabbit-antisera raised against
Rv0859c, Rv2031c, Rv2145c, Rv3692, or Rv0444c, respectively.
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Page 4 of 10metabolism, lipid metabolism, respiratory chain, oxida-
tion-phosphorylation and biotransformation. The func-
tions of these proteins have been well characterized in M.
tuberculosis, and included ATP synthase beta chain (EC
3.6.3.14) (AtpD), electron transfer flavoprotein (alpha sub-
unit) (FixB, EtfA), acyl-CoA thiolase (EC 2.3.1) (FadA),
and hydrodipicolinate reductase (EC 1.3.1.26) (DapB).
These proteins represented the major protein spots on the
gel. The second group included regulatory proteins whose
functions have been biochemically defined, for example:
transcription antitermination protein (NusG), methanol
dehydrogenase regulatory protein (MoxR2) and Rv0444c,
which is the SigK (RskA) regulator of certain M. tuberculo-
sis complex members [21,22]. The third group comprised
the 16 kDa virulence factor antigen HspX, which is speci-
fic to the M. tuberculosis complex and is essential to bacilli
survival, particularly during latency. This antigen has been
used to detect antibody isotypes in sera of TB patients sin-
gly or in combination with other antigens [23]. Using the
recombinant 38 kDa and 16 kDa antigens for immuno-
diagnosis provided sensitivities of 59% (culture positive)
and 54% (culture negative) and specificity of 98% in
patients with pulmonary TB. A recent study suggested
that antibody responses to the 16-kDa antigen may be
important for the detection of latent TB infections [24,25].
Wag31, whose synonym is Ag84, made up the fourth
group of proteins: those associated with cell wall and cell
processes. The remaining protein, Rv3040c, is of unknown
function. Undefined spots were considered to be either
protein mixtures necessitating further separation or pro-
teins present at concentrations below the detection limits
of the assay (less than 1 ng).
Recombinant protein expression and subcellular
characterization
Ten recombinant His-tagged H37Rv proteins were
cloned and expressed in this study. Six proteins were
expressed at high levels both in soluble (rRv2031c,
rRv0444c, rRv2145c, rRv3692) and insoluble (inclusion
body) aggregates (rRv0859c, rRv3040). As shown in Fig-
ure 2, the purified His-tag fusion proteins moved as sin-
gle bands on the sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) gels.
Initially, protein hydrophobicity was predicted by cal-
culating the grand average of hydropathy scores using
the ProtParam program http://www.expasy.org/tools/
protparam.html. A score of > 0.4 indicated a hydropho-
bic protein likely to be membrane-associated [26]. Using
these criteria, all of the identified spots from 2-DE were
characterized as hydrophobic (Table 1). The subcellular
location of five recombinant proteins was also investi-
gated by western blot analysis using rabbit-antisera
raised to the respective proteins. Four different subcellu-
lar fractions (culture filtrate, cytosol, cell membrane and
cell wall) were analyzed for immunoreactivity. The fide-
lity of the fractions was confirmed as described pre-
viously [27]. Except for Rv2145c, which was present in
culture filtrate and cell wall fractions, all proteins were
located in the cell membrane of M. tuberculosis H37Rv.
Several proteins were found in other locations as well as
the cell membrane: Rv0859c was present in both cell
wall and cell membrane fractions, Rv3692 was identified
in the cytosol and cell membrane fractions, Rv0444c
was present in the cytosol, cell wall and cell membrane
fractions, and Rv2031c was present in the cytosol and
cell membrane fractions. These data indicate that most
immunogenic proteins detected using the immunopro-
teomic assay were located in the outer membrane frac-
tions, suggesting that these proteins could function as
candidate detection antigens.
Evaluation of the serodiagnostic potential of the
recombinant proteins
All recombinant proteins were tested for their potential
value in the serodiagnosis of TB by ELISA. Serum from
60 patients infected with MDR M. tuberculosis and 20
patients infected with antibiotic-susceptible M. tubercu-
losis was used in the analyses. Only three proteins,
rRv2031c, rRv3692, and rRv0444c, were consistently
immunoreactive to patient serum and were subjected to
further evaluation under various combination strategies,
such as rRv2031c and rRv3692 with a ratio of 1:1, 1:2,
1:3, 2:1, 3:1, 3:2, etc. Figure 4 shows the IgG seroreactiv-
ity to partial combinations of recombinant proteins at
equal or mixed ratios. Combinations of rRv2031c and
rRv3692 or rRv2031c, rRv3692, and rRv0444c provided
Figure 4 TB serodiagnose for clinical samples applied with
different proteins. HC, healthy Mycobacterium bovis BCG-
vaccinated controls; S-TB, pulmonary tuberculosis patients infected
by antibiotic-sensitive M. tuberculosis strains; M-TB, pulmonary
tuberculosis patients infected by multi-drug resistant M. tuberculosis
strains.Serum reactivity to (A) Rv2031c and Rv3692 at a 1:1 ratio, (B)
Rv2031c and Rv3692 at a 2:1 ratio (C) Rv2031c and Rv3692 at a 3:1
ratio and (D) Rv2031c, Rv3692, and Rv0444c at a 1:1:1 ratio.
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Page 5 of 10significant levels of seroreactivity when probed with
serum taken from drug-resistant M. tuberculosis infec-
tions, compared with the serum collected from healthy
controls. An absorbance of 2 SD (standard deviation)
over the mean OD of the healthy controls was consid-
ered as the cut-off criterion for seropositivity. Under
these conditions, a combination of rRv2031c and
rRv3692 at a 2:1 ratio, and the combination of
rRv2031c, rRv3692, and rRv0444c with a ratio of 1:1:1,
g a v eas e n s i t i v i t yo f5 6 . 7 %a nd a specificity of 100%,
respectively (Table 2 and Figure 4). This indicated that
antigens in combination could be potentially used in the
serodiagnosis of drug-resistant TB. The use of a single
protein in the detection assay showed lower sensitivity
and specificity values than combinations of recombinant
proteins, further demonstrating the value of multi-com-
ponent detection formulations. Because the antibody
responses to M. tuberculosis infections are heteroge-
neous, the desired sensitivity and specificity in serodiag-
nostic tests may be achieved by a combination of several
proteins, or the fusion of several epitopes into a poly-
protein.
Biomarkers of infection disease can indicate normal or
pathogenic processes, or pharmacological responses to
therapeutic intervention. So biomarkers provide prog-
nostic information for individual patients or cohorts in
clinical trials, either about future health status. The
need for biomarkers in tuberculosis is most crucial in
three areas: to indicate reactivation risk and predict
treatment success for patients with latent M. tuberculo-
sis infection; to predict durable (non-relapsing) treat-
ment success for patients with active disease; and to
indicate protection from tuberculosis by new vaccines
for people other than those with active disease [18,28].
Peripheral blood is the most widely used source in clini-
cal practice, although biomarkers can be studied in any
tissue or body fluid(including urine, saliva, sputum and
breath), Genes, transcripts, proteins, lipids and metabo-
lites can all be measured in blood for biomarker studies
[29].
Although this study identified several interesting
immunoreactive M. tuberculosis proteins, not all could
be used for the serological diagnosis of drug-resistant
T B .T od a t ew eh a v ea n a l y z e di m m u n o g e n i cw h o l ec e l l
proteins that were resolved within the pI range of 4-7.
The antigens identified so far largely depended on the
combination of the source of the antigens, the immu-
noreactive immunoglobulin class (IgG or IgM) identi-
fied, stage of the diseases and ethnicity of the infected
population. The conditions of the immunoproteomic
approach (sample denaturation, loss of some proteins
under 2-DE conditions) may have impaired the identifi-
cation of additional antigens. An immunocapture proce-
dure in which antigens could be enriched from
subcellular fractions based on their reactivity with
immobilized serum from patients infected by MDR
could lead to the identification of novel candidate anti-
gens. This kind of approach has already been success-
fully applied for other diseases [30,31]. It would be of
interest to complete the database of potential antigen
candidates using non-denaturing and complementary
procedures.
Conclusions
Three candidate antigens, Rv2031c, Rv3692, and
Rv0444c, identified in this study appeared to have
greater antigenic activity. The antigens were therefore
tested in combination using ELISA assays to evaluate
the use of these proteins for the serodiagnosis of MDR
M. tuberculosis infections. The results demonstrated
that these antigens, when used in combination, were
more effective than when used singly, suggesting that
combinations of antigens may yield the desired level of
sensitivity without affecting specificity. The validation
phase of a diagnostic kit using a combination of
rRv2031c and rRv3692 against a large panel of sera
from patients infected with drug-resistant M. tuberculo-
sis and healthy controls is also in progress. The aim of
this work is to supply a commercial serodiagnostic test
for drug-resistant TB with sufficient sensitivity and
specificity.
To our knowledge, this is the first report that has
identified antigen candidates for identifying drug-resis-
tant TB using immunoproteomic analysis. Three candi-
date protein antigens in combination functioned
effectively in the identification of immunoreactive anti-
bodies from patients infected with MDR strains. While
Table 2 IgG seroreactivity to recombinant M. tuberculosis
proteins
Recombination
proteins
MDR
a Susceptible
b Healthy controls
Total/Pos(%) Total/Pos(%) Total/Pos(%)
Rv0859c 60/14(23.3) 20/1(5) 20/0(0)
Rv2031c 60/20(33.3) 20/2(10) 20/0(0)
Rv2145c 60/13(21.7) 20/0(0) 20/0(0)
Rv3692 60/22(37) 20/0(0) 20/1(5)
Rv0444c 60/15(25) 20/3(15) 20/0(0)
Rv3040 60/7(11.7) 20/2(10) 20/3(15)
Rv2031c: 1:1 60/33(55) 20/5(25) 20/0(0)
Rv3692 2:1 60/34(56.7) 20/10(50) 20/0(0)
3:1 60/21(35) 20/7(35) 20/1(5)
Rv2031c:Rv3692: 60/34(56.7) 20/9(45) 20/0(0)
Rv0444c(1:1:1)
a) Serum from multi drug-resistant M. tuberculosis infected patients.
b) Serum from antibiotic-susceptible M. tuberculosis infected patients.
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Page 6 of 10the cross-reactivity of the his tag and cleaved purified
his-tag free antibody, and cross activity with MTM, are
worth to further work to demonstrate.
Methods
Bacterial strains and culture conditions
M. tuberculosis strain TMC 102 [H37Rv] (ATCC num-
ber 27294) was provided by the Chinese Institute for the
Control of Pharmaceutical and Biologic Products. Five
clinical MDR M. tuberculosis isolates from different
patients were obtained from the Shanghai Pulmonary
Hospital. Their antibiotic susceptibility patterns were
determined using the Bactec 960 instrument (Becton
Dickinson Microbiology Systems, Sparks, MD, USA).
The minimal inhibitory concentrations were determined
using a 7H9 solid medium proportional method [32].
Strains were initially identified biochemically and then
confirmed by 16S rDNA gene sequencing.
Human sera
All patient serum samples were obtained from the
Shanghai Pulmonary Hospital, China.
Blood samples were drawn from TB patients shortly
after diagnosis (culture and/or acid-fast bacillus smear
positive and chest X-ray positive). All donors were
between the ages of 18 and 65 and provided informed
consent.
Serum was collected from patients infected with drug-
resistant M. tuberculosis (n = 20) or from patients
infected with drug-susceptible M. tuberculosis (n = 20),
then randomly divided into four different pools. Each
pool included five serum samples and was used for
immunoproteomic analysis. Serum from patients
infected with drug-resistant M. tuberculosis (n = 60)
and drug-susceptible M. tuberculosis (n = 20) was col-
lected for ELISA analysis of IgG reactivity to recombi-
nant antigens. Serum from healthy volunteers was used
as a negative control (n = 20). Serum reactivity to
recombinant M. tuberculosis antigens were assessed by
ELISA as described previously [20].
Isolation of M. tuberculosis proteins
Whole cell extracts were harvested from M. tuberculosis
during early mid-log growth phase, as described pre-
viously [12]. Approximately 10
9 bacteria were sonicated
in the presence of proteinase inhibitors and then treated
with 8 M urea, 2 M thiourea, 70 mM dithiothreitol,
0.5% Biolyte (pH 4-7), 400 μg/mL n-octyl-D-glucopyra-
noside, and 4% CHAPS to completely denature and
reduce proteins. Supernatants were then collected after
centrifugation at 10 000 × g for 15 min. Three subcellu-
lar fractions (cell wall, membrane, and cytosolic frac-
tions) of M. tuberculosis cell lysates were obtained by
differential centrifugation as described previously [12].
Preparation of culture filtrate protein was also per-
formed as described previously [33].
Two-dimensional gel electrophoresis
Proteins were identified by excision and in-gel trypsini-
zation of respective spots from silver-stained gels as
described previously [10]. The analyses were performed
using a 4700 MALDI-TOF/TOF Proteomics Analyzer
(Applied Biosystems, Foster City, CA, USA) equipped
with a 355 nm Nd:YAG laser. Combined MS and MS/
MS spectra were submitted to MASCOT version 2.1
(Matrix Science, London, UK) using GPS Explorer soft-
ware version 3.6 (Applied Biosystems). MASCOT pro-
tein scores (based on combined MS and MS/MS
spectra) greater than 72 were considered statistically sig-
nificant (p ≤ 0.05). The individual MS/MS spectrum
with statistically significant (confidence interval > 95%)
best ion score (based on MS/MS spectra) were accepted.
The number of identified peptides, sequence coverage
and number of MS/MS identified peptides were consid-
ered during protein identification. To eliminate the
redundancy of proteins that appeared in the database
under different names and accession numbers, the sin-
gle-protein member belonging to the species Mycobac-
terium with the highest protein score (top rank) was
singled out from the multi-protein family [34]. Isoelec-
tric focusing (IEF) was performed using an IPGphor IEF
system (Bio-Rad, Hercules, CA, USA), and 2-DE was
performed according to the manufacturer’si n s t r u c t i o n s .
Briefly, a 17 cm IPG strip pH 4-7 was rehydrated over-
night in rehydration solution (7 M urea, 2 M thiourea,
1% ASB-14, 0.5% Triton X-100, 0.5% 3-10 carrier
ampholytes, 55 mM dithiothreitol, 0.002% bromophenol
blue) containing 80 μg of proteins in a total volume of
360 μL. Focusing was conducted by stepwise voltage
increases as follows: 500 V for 2 hours, 1000 V for 2.5
hours, 8000 V for 5 hours and 8000 V until the total
volt-hours reached 80 kVh. Following IEF separation,
strips were equilibrated twice (14 min each time) in 8
mL of SDS equilibration buffer (150 mM Tris-Cl, pH
8.8; 6 M urea, 20% glycerol, 2% SDS, 0.002% bromophe-
nol blue) containing 100 mg dithiothreitol and 250 mg
iodoacetamide. IPG strips were then placed over a
12.5% vertical polyacrylamide gel (0.75 mm thick, 18 cm
wide, and 24 cm long), and electrophoresis was carried
out at 30 mA until the bromophenol blue had run to
the bottom of the gel. Second-dimension PAGE gels
were run in duplicate, with the first gel used for immu-
noblotting and the second silver stained to serve as a 2-
D reference map [35]. Gels were scanned using Molecu-
lar Image Fx (Bio-Rad) and analyzed with PDQuest ver-
sion 6.0 software (Bio-Rad). For each sample, IPG gels
were electrophoresed in triplicate on separate occasions.
The gel images were normalized according to the total
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Page 7 of 10quantity in the analysis set as Griffin TJ [36]. Relative
comparison of intensity abundance of differential pro-
tein spots was performed with Student’st - t e s t .A n yd i f -
ference with a P-value ≤ 0.05 was considered statistically
significant.
2-DE western blotting
Proteins subjected to 2-DE gel electrophoresis were
transferred onto 0.45 mm Immobilon-P PVDF mem-
branes (Millipore, Billerica, MA, USA) using a semi-dry
electro-blotter (Bio-Rad) with Towbin transfer buffer, at
a constant current of 1 mA/cm
2 for 80 min. PVDF
membranes were incubated overnight in PBST (9 mM
sodium phosphate, 0.15 M NaCl, and 0.05% v/v Tween
20) containing 5% (w/v) skim milk powder at 4°C with
constant rotation. Following three 10-min washes with
PBST, blots were incubated for 1 hour at 37°C with
human sera diluted 1:400 in PBST containing 2% (w/v)
skim milk powder. Human sera from uninfected volun-
teers and patients infected with drug-susceptible M.
tuberculosis were used as negative controls. After wash-
ing with PBST, blots were incubated with biotinylated
anti-human IgG (Vector Laboratories, Burlingame, CA,
USA) at a dilution of 1:20, 000 for 1 hour at room tem-
perature. Before and after the addition of the secondary
antibody, membranes were washed four times for 15
m i ni nP B S T .M e m b r a n e sw e r et h e nw a s h e dw i t h5 0
mM Tris-HCl buffer (pH 7.4) and developed with strep-
tavidin-conjugated alkaline phosphatase (Vector Labora-
tories). Membranes were then incubated with nitro blue
tetrazolium/5-Bromo-4-chloro-3-indolyl phosphate
detection substrate. Immunoblotting experiments were
conducted in triplicate and no variation was observed
between results.
Tryptic digests and MALDI-TOF-MS
Proteins were identified by excision and in-gel trypsini-
zation of respective spots from silver-stained gels as
described previously [10]. The analyses were performed
using a 4700 MALDI-TOF/TOF Proteomics Analyzer
(Applied Biosystems, Foster City, CA, USA) equipped
with a 355 nm Nd:YAG laser. Combined MS and MS/
MS spectra were submitted to MASCOT version 2.1
(Matrix Science, London, UK) using GPS Explorer soft-
ware version 3.6 (Applied Biosystems). MASCOT pro-
tein scores (based on combined MS and MS/MS
spectra) greater than 72 were considered statistically sig-
nificant (p ≤ 0.05). The individual MS/MS spectrum
with statistically significant (confidence interval > 95%)
best ion score (based on MS/MS spectra) were accepted.
The number of identified peptides, sequence coverage
and number of MS/MS identified peptides were consid-
ered during protein identification. To eliminate the
redundancy of proteins that appeared in the database
under different names and accession numbers, the sin-
gle-protein member belonging to the species Mycobac-
terium with the highest protein score (top rank) was
singled out from the multi-protein family [34].
Expression and purification of recombinant proteins and
antisera production
The coding sequence for each protein was amplified from
M. tuberculosis strain H37Rv genomic DNA by PCR. The
specific primers included sequences for appropriate
restriction sites to enable cloning. The primers and para-
meters for thermal cycler amplification are shown in
Table 3. PCR products were cloned into pET28a or
pET30a vectors (EMD Biosciences, San Diego, CA, USA),
resulting in the addition of a 6 × His N-terminal leader
sequence to each coding sequence. The fidelity of the
recombinant plasmid was confirmed by sequencing. Plas-
mids encoding respective fusion proteins were trans-
formed into Escherichia coli BL21 (DE3). Cell cultures
were grown to OD600 0.6-0.8 in Luria Bertani broth con-
taining 100 μg/mL kanamycin. Protein induction was then
carried out by adding 1 mM isopropyl-D-thiogalactoside
for 5 hours at 37°C. Induced cells were harvested and
washed with cold 50 mM sodium phosphate buffer (pH
7.9) and centrifuged at 8 000 × g for 15 min. The cell pel-
let was resuspended in Ni-NTA lysis buffer (300 mM
NaCl, 50 mM sodium phosphate buffer, pH 7.9) at 50 g/
mL wet weight. Bacteria were lysed by sonication and the
lysate was centrifuged at 12 000 × g for 30 min. Superna-
tants were then loaded onto a Ni-NTA His-Binding col-
umn (Novagen, Madison, WI, USA) and His-tagged
proteins were eluted using elution buffer containing var-
ious imidazole concentrations. Pellets were dissolved in
lysis buffer in the presence of 8 M urea and then purified
using a Ni-NTA His-Binding column as described above.
The purified proteins were dialyzed against 5 mM Tris-
HCl buffer (pH 7.5) containing 100 mM NaCl and 3% (v/
v) glycerol and quantified using Bradford reagent.
Procedures for antiserum production were based on
standard protocols [37]. Briefly, 3-month-old New Zeal-
and White rabbits were immunized with recombinant
proteins emulsified with incomplete Freund’sa d j u v a n t
and boosted four times at 2-week intervals, and antisera
collection was performed 7 days after the last boost.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assays (ELISA) were
used to assess the humoral response in humans to the
recombinant proteins identified in this study. Ninety-
six-well microtitre plates (Nalge Nunc International,
Rochester, NY, USA) were coated with 500 ng of recom-
binant protein antigen dissolved in 100 μLo f0 . 0 5M
carbonic acid buffer, and incubated overnight at 4°C in
a humidified chamber. Wells were washed three times
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bovine serum albumin (w/v) in PBS) for 2 hours at 37°C,
and then washed three times with PBST. Sera corre-
sponding to the different clinical groups were diluted
1:400 in blocking buffer and 100 μL was added to each
antigen-coated well. Following incubation for 1 hour at
37°C, the plates were washed five times with PBST and
then incubated with horseradish peroxidase-conjugated
goat anti-human IgG at 37°C for 1 hour. Antibody bind-
ing was detected using o-phenylenediamine tetrahy-
d r o c h l o r i d e( S i g m aA l d r i c h ,S a i n tL o u i s ,M O ,U S A )
dissolved (1 μL/mL) in citrate-phosphate buffer (pH 5.4)
and H2O2. The reaction was stopped by the addition of
50 μLo f0 . 5MH 2SO4, and absorbance values were mea-
sured at 492 nm in an ELISA reader (Bio-Rad). Experi-
ments were repeated at least twice with similar results.
The ELISA results were analyzed using cut-off values
equal to the mean optical density for the healthy control
serum samples plus two standard deviations. Any sam-
ple exhibiting an absorbance value above the cut-off
value was considered to be positive. For statistical analy-
sis, the differences between groups of TB patients and
healthy controls were calculated by the independent-
samples t-test using the Statistics Package for Social
Science (SPSS 13.0, Chicago, IL, USA), with p < 0.05
considered to be statistically significant.
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Table 3 Primers sets for genes amplified by PCR
Gene Primer sequences(5’-3’) Restriction site used
Rv1310 5’ CGAATTCATGACTACCACTGCCGAAAAG 3’ EcorI
5’ TATAAGCTTTCACAGCTTGGCGCCGAGAC 3’ HinD III
Rv3028c 5’ TAGGATCCATGGCTGAAGTACTGGTGCTC 3’ BamHI
5’ TATAAGCTTCTAGCCCTTGCGGGCCTTG 3’ HinD III
Rv3040 5’ TAGGATCCATGAATTCACCTCGCGAGCC 3’ BamHI
5’ TATAAGCTTTCACAGCGGCCACCCGGTC 3’ HinD III
Rv2145c 5’ TAGGATCCATGCCGCTTACACCTGCCG 3’ BamHI
5’ TAGAGCTCCTAGTTTTTGCCCCGGTTGAAT 3’ SacI
Rv0639 5’ TAGGATCCGTGACTACCTTCGACGGTG 3’ BamHI
5’ GACAAGCTTCTAGATCTTGGAGACTTGGCC 3’ HinD III
Rv3692 5’ TAGGATCCGTGACACAGTCCGCGTCCAAC 3’ BamHI
5’ TGTAAGCTTCTAGCGGGGCACCGGAACC 3’ HinD III
Rv0444c 5’ TGGATCCATGACTGAACATACCGATTTTGAG 3’ BamHI
5’ TATAAGCTTTCACCCGAGCGGCAGCTCGGC 3’ HinD III
Rv2031c 5’ TAGGATCCATGGCCACCACCCTTCCCGT 3’ BamHI
5’ GCGAAGCTTTCAGTTGGTGGACCGGATCTG 3’ HinD III
Rv0859c 5’ ATGGATCCATGTCCGAAGAAGCCTTCATCTAC 3’ BamHI
5’ TATAAGCTTTTAAACCCTCTCGATGATCGTCGC 3’ HinD III
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